Now, programmed cell death 1 (PD-1) inhibitor plus chemotherapy has been approved for the first-line treatment of advanced ESCC based on the appreciable outcomes in ESCORT-1st (5) and Checkmate648 (6). This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.